Cerevel Therapeutics (CERE) Earnings Date, Estimates & Call Transcripts → The only AI company to buy (From Porter & Company) (Ad) Free CERE Stock Alerts $41.00 +0.37 (+0.91%) (As of 10:34 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 7EstimatedActual EPS (May. 8) -$0.73 Missed By -$0.12 Consensus EPS (May. 8) -$0.61 Get Cerevel Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CERE and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCERE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CERE Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Capital TrendsEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in semiconductor technologies. A critical next step to satisfy the massive processing needs of AI and quantum computing.Click here to learn how this overlooked mineral shapes the world today Cerevel Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.67)($0.67)($0.67)Q2 20241($0.63)($0.63)($0.63)Q3 20241($0.67)($0.67)($0.67)Q4 20241($0.69)($0.69)($0.69)FY 20244($2.66)($2.66)($2.66)CERE Earnings Date and InformationCerevel Therapeutics last announced its quarterly earnings data on May 8th, 2024. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.12. Cerevel Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.63) to ($2.86) per share. Cerevel Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off prior year's report dates.Read More Cerevel Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/7/2024(Estimated)------- 5/8/2024Q1 2024($0.61)($0.73)($0.12)($0.73)--11/1/2023Q3 2023($0.63)($0.61)+$0.02($0.61)-- 8/2/2023Q2 2023($0.65)($0.63)+$0.02($0.63)-- 5/3/2023Q1 2023($0.67)($0.67)-($0.67)-- 2/22/2023Q4 2022($0.64)($0.59)+$0.05($0.59)--11/8/2022Q3 2022($0.62)($0.66)($0.04)($0.66)-- Get the Latest News and Ratings for CERE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/1/2022Q2 2022($0.48)($0.62)($0.14)($0.61)-- 5/10/2022Q1 2022($0.44)($0.46)($0.02)($0.46)-- 3/1/2022Q4 2021($0.41)($0.40)+$0.01($0.40)-- 11/10/2021Q3 2021($0.40)($0.43)($0.03)($0.43)-- 8/11/2021Q2 2021($0.41)($0.42)($0.01)($0.42)-- 5/16/2021Q1 2021($0.41)($0.40)+$0.01($0.40)-- 3/24/2021Q4 2020($0.37)($0.27)+$0.10($0.27)-- 11/16/2020Q3 2020-($4.83)($4.83)($4.17)-- Cerevel Therapeutics Earnings - Frequently Asked Questions When is Cerevel Therapeutics's earnings date? Cerevel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates. Learn more on CERE's earnings history. Did Cerevel Therapeutics beat their earnings estimates last quarter? In the previous quarter, Cerevel Therapeutics (NASDAQ:CERE) missed the analysts' consensus estimate of ($0.61) by $0.12 with a reported earnings per share (EPS) of ($0.73). Learn more on analysts' earnings estimate vs. CERE's actual earnings. How much profit does Cerevel Therapeutics generate each year? Cerevel Therapeutics (NASDAQ:CERE) has a recorded net income of -$432.84 million. CERE has generated $0.00 earnings per share over the last four quarters. What is Cerevel Therapeutics's EPS forecast for next year? Cerevel Therapeutics's earnings are expected to decrease from ($2.63) per share to ($2.86) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Ascendis Pharma A/S Earnings Legend Biotech Earnings Viking Therapeutics Earnings Insmed Earnings Intra-Cellular Therapies Earnings Jazz Pharmaceuticals Earnings Elanco Animal Health Earnings Blueprint Medicines Earnings Roivant Sciences Earnings Ionis Pharmaceuticals Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New HeightsTD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers This page (NASDAQ:CERE) was last updated on 6/4/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyElon Musk’s Final Masterpiece: “X-9840”Paradigm PressAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldDoes this make you sick?Allegiance GoldWas the Great Financial Crisis fun?Brooks EnterprisesEverything from semiconductors to space shuttles depend on this overlooked mineralCapital TrendsCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.